TABLE 2.
Hazard ratios for incidence of SARS‐CoV‐2 infection and of severe, critical, or fatal COVID‐19 in the (A) two‐dose analysis and (B) three‐dose analysis.
| A. Two‐dose analysis | BNT162b2 cohort a | mRNA‐1273 cohort a |
|---|---|---|
| Main analysis | ||
| Sample size | 390,495 | 390,495 |
| Number of incident infections | 37,097 | 36,076 |
| Total follow‐up time (person‐weeks) | 32,081,665 | 32,160,114 |
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 11.6 (11.5–11.7) | 11.2 (11.1–11.3) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.03 (1.02–1.05) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.03 (1.02–1.05) | |
| Unadjusted hazard ratio for severe, critical, or fatal COVID‐19 disease (95% CI) | 1.30 (0.81–2.10) | |
| Adjusted hazard ratio for severe, critical, or fatal COVID‐19 disease (95% CI) b | 1.31 (0.81–2.11) | |
| Subgroup analyses | ||
| No prior infection | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 11.7 (11.6–11.9) | 11.4 (11.3–11.5) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.03 (1.01–1.04) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.03 (1.02–1.05) | |
| Prior pre‐omicron infection | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 9.9 (9.6–10.3) | 9.5 (9.2–9.8) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.05 (1.00–1.10) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.05 (1.00–1.10) | |
| Prior omicron infection | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 7.6 (4.2–13.7) | 3.4 (1.4–8.2) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 2.23 (0.78–6.43) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 2.43 (0.84–7.02) | |
| Prior pre‐omicron and omicron infections | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | — | — |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | — | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | — | |
| B. Three‐dose analysis | BNT162b2 cohort a | mRNA‐1273 cohort a |
|---|---|---|
| Main analysis | ||
| Sample size | 177,422 | 177,422 |
| Number of incident infections | 16,907 | 15,405 |
| Total follow‐up time (person‐weeks) | 16,947,840 | 17,048,557 |
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 10.0 (9.8–10.1) | 9.0 (8.9–9.2) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.10 (1.08–1.13) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.11 (1.09–1.13) | |
| Unadjusted hazard ratio for severe, critical, or fatal COVID‐19 disease (95% CI) | 1.00 (0.20–4.97) | |
| Adjusted hazard ratio for severe, critical, or fatal COVID‐19 disease (95% CI) | 1.00 (0.20–4.94) | |
| Subgroup analyses | ||
| No prior infection | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 10.3 (10.1–10.4) | 9.3 (9.1–9.4) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.10 (1.08–1.13) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.11 (1.09–1.14) | |
| Prior pre‐omicron infection | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 8.4 (8.0–8.7) | 8.2 (7.8–8.6) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.02 (0.96–1.09) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.02 (0.96–1.09) | |
| Prior omicron infection | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 8.9 (8.0–10.0) | 5.7 (4.9–6.5) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.58 (1.32–1.89) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.59 (1.33–1.90) | |
| Prior pre‐omicron and omicron infections | ||
| Incidence rate of infection (per 10,000 person‐weeks; 95% CI) | 10.4 (7.1–15.3) | 5.8 (3.5–9.7) |
| Unadjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) | 1.78 (0.94–3.36) | |
| Adjusted hazard ratio for SARS‐CoV‐2 infection (95% CI) b | 1.97 (1.04–3.73) | |
Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
a
Cohorts were matched exactly one to one by sex, 10‐year age group, nationality, number of coexisting conditions, prior infection status, and calendar week of the second vaccine dose in the two‐dose analysis and calendar week of the third dose in the three‐dose analysis.
b
Adjusted for sex, 10‐year age group, nationality, number of coexisting conditions, and calendar week of the second vaccine dose in the two‐dose analysis and calendar week of the third dose in the three‐dose analysis.